Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanezumab in pain due to schwannomatosis
NCT04163419Phase 2Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Apr 2020
- Primary completion
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tanezumab in schwannomatosis, sponsored by Massachusetts General Hospital. Primary endpoint: Change in pain level at 8 weeks. Started Apr 2020; status: active, not recruiting.
02
Drugs
tanezumab
03
Conditions
schwannomatosis
Beyond the preview
Go deeper on NCT04163419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04163419.